Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Elephas Biosciences, Neuberg Partner on Immuno-therapy Testing The Story: Elephas Biosciences has partnered with Neuberg Diagnostics to bring its elive live-tissue platform to India, with a clinical t...
Summary: The Top 10 Indian Pharmaceutical Companies of 2026 demonstrate the continued strength and global competitiveness of India’s pharmaceutical sector, led by Sun Pharmaceutical Industries, ...
Summary The Top 10 Generic Pharmaceutical Companies of 2025 highlight the continued growth and resilience of the global generics industry, led by Sandoz, Sun Pharma, and Fosun Pharma....
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: CORONA Remedies is using the Wokadine acquisition to buy its way into India’s ₹648 crore povidone-iodine market with a #2-ranked, 46‑year-old antise...
Key Highlights: Implications: Usema adds another early DCGI‑approved semaglutide brand to India’s GLP‑1 wave, giving USV a bioequivalent, locally manufactured injectable that fits neatly i...
Key Highlights: Implications: Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~...
